Tricia Mullins

Tricia Mullins, BCPA, serves as the Executive Director and Global Head of Early Patient Engagement and Professional Societies at BeiGene since January 2022, leading initiatives that amplify patient voices across more than 50 programs globally. In parallel, Tricia co-chairs the Board of Directors at the Neuromuscular Disease Foundation, focusing on advocacy and funding for GNE Myopathy research. As President of RARE PAC, Tricia provides consulting services in patient advocacy and engagement, specializing in gene therapy and commercialization strategies. Tricia also holds the position of Global Head of Patient Advocacy at Atara Biotherapeutics, where efforts include creating advocacy infrastructure for rare oncologic conditions and collaboration with professional societies. Previous roles at Halozyme Therapeutics, Horizon Pharma, Esperion, Global Genes, AbbVie, and Novelion Therapeutics reflect a consistent commitment to patient advocacy, education, and access, with notable achievements including receiving the CEO Award at Halozyme in 2019. Tricia’s educational background includes studies at the University of Miami and St. John's University.